ESC 365 - Efficacy and safety of dronedarone by duration of atrial fibrillation history: a post-hoc analysis of the ATHENA trial

ESC Premium Access

Efficacy and safety of dronedarone by duration of atrial fibrillation history: a post-hoc analysis of the ATHENA trial

Session: Poster Session 5 - Atrial fibrillation and oral anticoagulation 5

Topic: Treatment

Speaker: Professor C. Blomstrom-Lundqvist (Orebro, SE)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor Carina Blomstrom-Lundqvist

Orebro University Hospital, Orebro (Sweden)

40 presentations

8 followers

8 more presentations in this session

Direct comparison of dabigatran, apixaban, rivaroxaban and edoxaban for effectiveness and safety among patients with non-valvular atrial fibrillation

Speaker: Doctor E. Choi (Seoul, KR)

Treatment persistence of patients with atrial fibrillation on VKA or NOAC: Data from GLORIA-AF Phase III 1-year interim analysis

Speaker: Professor G. Lip (Liverpool, GB)

Clinical characteristics and 1-year outcomes in atrial fibrillation patients with or without history of intracranial haemorrhage treated with edoxaban: snapshot analysis of the Global ETNA-AF program

Speaker: Professor P. Kirchhof (Hamburg, DE)

Dual antithrombotic therapy is similarly effective to triple therapy in preventing thrombotic events in patients with atrial fibrillation and acute coronary syndrome

Speaker: Professor Z. Motovska (Prague, CZ)

Use of direct oral anticoagulants in patients with atrial fibrillation having a history of intracranial hemorrhage

Speaker: Doctor T. Chao (Taipei, TW)

Access the full session

Poster Session 5 - Atrial fibrillation and oral anticoagulation 5

Speakers: Professor C. Blomstrom-Lundqvist, Doctor E. Choi, Professor G. Lip, Professor P. Kirchhof, Professor Z. Motovska...

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources